Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 4/20 | 0.54 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16092102 | 0.83 | PTPN1 (0.56) | POLBCYP1A2CYP3A4CYP2D6PTPN1 | |
| SCHEMBL3282190 | 0.82 | PTPN1 (0.62) | POLBCYP1A2CYP3A4CYP1A1CYP2D6 | |
| SCHEMBL10696833 | 0.79 | POLB (0.55) | POLBCYP1A2CYP3A4CYP1A1CYP2D6 | |
| SCHEMBL6276675 | 0.79 | NAPRT (0.56) | IDO1NAPRTCYP1A2CYP3A4MAPK1 | |
| SCHEMBL6279379 | 0.79 | NAPRT (0.56) | IDO1NAPRTCYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL15395615 | 0.78 | PLOD2 (0.65) | POLBCYP1A2CYP3A4CYP1A1CYP2D6 | |
| Bromide SCHEMBL2691231 | 0.78 | HPGD (0.62) | IDO1NAPRTCYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL2473843 | 0.77 | NAPRT (0.53) | IDO1NAPRTCYP1A2CYP3A4CYP2D6 | |
| SCHEMBL16092091 | 0.76 | PTPN1 (0.48) | POLBCYP1A2CYP3A4CYP1A1CYP2D6 | |
| SCHEMBL22745166 | 0.76 | PTPN1 (0.48) | POLBCYP1A2CYP3A4CYP1A1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3845546-B1 | COMPLEXES | JOHNSON MATTHEY PLC (GB) | 2024-06-19 | — | — | EP | disclosed |
| EP-3842421-B1 | COMPLEXES | JOHNSON MATTHEY PLC (GB) | 2024-06-12 | — | — | EP | disclosed |
| US-11649258-B2 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11649258-B2 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2023-05-16 | — | — | US | disclosed |
| US-11649258-B2 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2023-05-16 | — | — | US | disclosed |
| EP-3845546-A1 | COMPLEXES | Johnson Matthey Public Limited Company (GB) | 2021-07-07 | — | — | EP | disclosed |
| EP-3845546-A1 | COMPLEXES | Johnson Matthey Public Limited Company (GB) | 2021-07-07 | — | — | EP | disclosed |
| EP-3842421-A1 | COMPLEXES | Johnson Matthey Public Limited Company (GB) | 2021-06-30 | — | — | EP | disclosed |
| EP-3842421-A1 | COMPLEXES | Johnson Matthey Public Limited Company (GB) | 2021-06-30 | — | — | EP | disclosed |
| US-20210163516-A1 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2021-06-03 | — | — | US | disclosed |
| US-20190241589-A1 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2019-08-08 | — | — | US | disclosed |
| US-20190241589-A1 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2019-08-08 | — | — | US | disclosed |
| US-10253056-B2 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2019-04-09 | — | — | US | disclosed |
| US-10253056-B2 | Complexes | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2019-04-09 | — | — | US | disclosed |
| US-20170121357-A1 | COMPLEXES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-05-04 | — | — | US | disclosed |
| US-20170121357-A1 | COMPLEXES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-05-04 | — | — | US | disclosed |
| US-20170121357-A1 | COMPLEXES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2017-05-04 | — | — | US | disclosed |
| EP-3154945-A1 | COMPLEXES | Johnson Matthey Public Limited Company (GB) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015189554-A1 | COMPLEXES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2015-12-17 | — | — | WO | disclosed |
| WO-2015189554-A1 | COMPLEXES | JOHNSON MATTHEY PUBLIC LIMITED COMPANY (GB) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190241589-A1 | Complexes | RDX, C5, RPS4X | POLB 1594/4885IDO1 635/4885NAPRT 4789/4885 |
| US-20210163516-A1 | Complexes | AP2M1, AP1M1, INF2 | POLB 1033/4885IDO1 370/4885NAPRT 4577/4885 |
| US-10253056-B2 | Complexes | CYCS, AP1M1, SOD1 | POLB 233/4885IDO1 612/4885NAPRT 3959/4885 |
| US-20170121357-A1 | COMPLEXES | CYCS, AP1M1, SOD1 | POLB 233/4885IDO1 612/4885NAPRT 3959/4885 |
| US-11649258-B2 | Complexes | AP2M1, AP1M1, INF2 | POLB 1033/4885IDO1 370/4885NAPRT 4577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.